Christopher Mark Thompson

US Patent:

8324158, Dec 4, 2012

Filed:

Jul 12, 2007

Appl. No.:

12/373556

Inventors:

Neal McCarty - Atlanta GA, US
Christopher H. Thompson - Atlanta GA, US
Julia Kubanek - Decatur GA, US

Assignee:

Georgia Tech Research Corporation - Atlanta GA

International Classification:

A61K 38/16
C07K 14/435
A61P 1/12

US Classification:

514 74, 514 213, 514867, 530324, 530855

Abstract:

Compositions and methods of using scorpion venom peptide that is a ligand for ClC channels are provided. One aspect provides a pharmaceutical composition containing an amount of GaTx2 effective to inhibit ClC activity. Methods of treating a disorder or symptom of a disorder related to aberrant ClC channel activity are also provided.

US Patent:

20130202626, Aug 8, 2013

Filed:

Jul 27, 2011

Appl. No.:

13/813083

Inventors:

Thomas Linke - Odenton MD, US
William K. Wang - McLean VA, US
Ambarish Shah - Boyds MD, US
Hasige Sathish - Germantown MD, US
Alan Hunter - Gaithersburg MD, US
Christopher Thompson - Gaithersburg MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

C07K 1/18
C07K 17/02

US Classification:

4241831, 5303917

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography.

US Patent:

20210395370, Dec 23, 2021

Filed:

Sep 2, 2021

Appl. No.:

17/465092

Inventors:

- Cambridge, GB
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
B01D 15/16
B01D 15/36
B01J 41/14
B01J 41/20
A61K 47/68
C07K 1/18
C07K 17/02
A61K 39/395
A61K 47/02

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20200407423, Dec 31, 2020

Filed:

Jun 15, 2020

Appl. No.:

16/901812

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
A61K 47/64
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

US Patent:

20200231680, Jul 23, 2020

Filed:

Feb 10, 2020

Appl. No.:

16/786634

Inventors:

- Cambridge, GB
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
B01D 15/16
B01D 15/36
B01J 41/14
B01J 41/20
A61K 47/68
C07K 1/18
C07K 17/02
A61K 39/395
A61K 47/02

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20180371094, Dec 27, 2018

Filed:

Sep 7, 2018

Appl. No.:

16/124441

Inventors:

- Gaithersburg MD, US
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
A61K 47/68
B01D 15/16

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20180203115, Jul 19, 2018

Filed:

Nov 27, 2017

Appl. No.:

15/822285

Inventors:

- Chantilly VA, US
Christopher THOMPSON - Alexandria VA, US

Assignee:

Digital Signal Corporation - Chantilly VA

International Classification:

G01S 17/08
G01S 7/487

Abstract:

Systems and methods for determining ranges to a target disposed behind a transparent surface are described. A target acquisition system receives a plurality of lidar returns, at least some of which are from a target and at least some of which are from a transparent surface. The lidar returns correspond to a portion of a lidar signal generated by a lidar, directed toward the target, and reflected back to the lidar from either the target or the transparent surface. A range measurement for each of the plurality of lidar returns is determined. The target acquisition system generates a histogram of the range measurements. The histogram includes an array including a plurality of range bins. Each range bin defines a unique portion of a predetermined distance out from the lidar. The histogram further includes a count associated with each respective range bin. The count corresponds to a number of range measurements falling within the unique portion of the predetermined distance corresponding to that respective range bin. In some implementations of the invention, the target acquisition system determines which of the range measurements correspond to the target based on the histogram. In some implementations of the invention, the target acquisition system determines which of the range measurements correspond to the transparent surface based on the histogram.

US Patent:

20180105575, Apr 19, 2018

Filed:

Mar 11, 2016

Appl. No.:

15/557358

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.